Meningitis Vaccine Eligibility Under Scrutiny After Kent Outbreak
Health experts are urgently considering expanding routine meningitis B vaccination to a broader population in response to a fatal outbreak in Kent. The Joint Committee on Vaccination and Immunisation (JCVI) has initiated a review after Health Secretary Wes Streeting requested a re-examination of eligibility criteria, aiming to protect more individuals beyond current qualifications.
Outbreak Details and National Implications
On Friday, the UK Health Security Agency confirmed 18 cases of meningitis linked to the Kent outbreak, with an additional 11 cases under investigation. Two fatalities have been reported, heightening concerns as students prepare to travel home for Easter, potentially spreading the disease outside the county. Dr. Anjan Ghosh, Kent County Council's Director of Public Health, warned that sporadic cases could emerge across the UK over the next month, though he stressed that new outbreaks are highly unlikely.
Vaccination Policy and Cost-Effectiveness Debates
The JCVI, which advises all four UK nations on immunisation, previously deemed a catch-up campaign for young people born before 2015—when the MenB vaccine was introduced for infants—as not cost-effective. Experts note that protection from the vaccine lasts only a few years and does not prevent bacterial transmission. Dr. Michael Head from the University of Southampton suggested adding MenB to routine year 9 jabs, leveraging existing school-based immunisation systems. However, Prof. Andy Pollard of the Oxford Vaccine Group expressed skepticism, citing Treasury rules on cost-effectiveness as a barrier to expansion.
Public Response and Vaccine Availability
The family of Juliette Kenny, a teenager who died from meningitis on March 15, is campaigning for routine access to the MenB vaccine for teenagers and young adults, describing their loss as immeasurable. Meanwhile, health officials assure that vaccine stocks are ample, with over 4,500 people already vaccinated in Kent and more than 10,561 doses of antibiotics distributed. Ed Waller of NHS Kent and Medway emphasized efforts to increase vaccination capacity over the weekend.
Genetic Analysis and Future Outlook
Initial genetic analysis indicates that the Bexsero vaccine currently offered in Kent should provide protection against the MenB strain involved in the outbreak, which belongs to a group circulating in the UK for about five years. The JCVI's review will assess whether updated policies, such as booster rollouts for teenagers, could mitigate future risks, balancing health benefits against economic constraints.
